Enterprise Products Partners LP
Change company Symbol lookup
Select an option...
EPD Enterprise Products Partners LP
STLB Sterling Business Solutions Inc
CITY Avalon Correctional Services Inc
TEVJF Teva Pharmaceutical Industries Ltd
UMBF UMB Financial Corp
OXM Oxford Industries Inc
ICON Iconix Brand Group Inc
BAC Bank of America Corp
ON ON Semiconductor Corp
EQNR Equinor ASA
Go

Energy : Oil, Gas & Consumable Fuels | Large Cap Value
Company profile

Enterprise Products Partners L.P. (Enterprise) is a provider of midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals and refined products in North America. The Company's segments include NGL Pipelines & Services; Crude Oil Pipelines & Services; Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services. The Company's midstream energy operations include natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage, and import and export terminals, including liquefied petroleum gas (LPG); crude oil gathering, transportation, storage and terminals; petrochemical and refined products transportation, storage, export and import terminals, and related services, and a marine transportation business that operates primarily on the United States inland and Intracoastal Waterway systems.

Premarket

Last Trade
Delayed
$19.28
0.60 (3.21%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$18.68
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
16,926

10-day average volume:
9,023,221
16,926

Inovio's stock gains on early data testing its COVID-19 vaccine in animals

7:31 am ET May 20, 2020 (MarketWatch)
Print

Shares of Inovio (INO) gained 22.8% in premarket trading on Wednesday after the company said its COVID-19 vaccine candidate demonstrated neutralizing antibodies in animals. The data, published in Nature Communications (https://www.nature.com/articles/s41467-020-16505-0), is from a preclinical study, meaning it does not include information about how the investigational vaccine reacts in humans but in mice and guinea pigs. Inovio is currently conducting a Phase 1 clinical trial testing the DNA vaccine candidate in people; early data from that study is expected to be announced in June. "The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials," Dr. Kate Broderick, Inovio's team lead for COVID-19 vaccine development, said in a news release. There are no proven vaccines that prevent against infections with COVID-19. Moderna Inc. (MRNA)announced early positive results (http://www.marketwatch.com/story/modernas-stock-soars-on-positive-early-stage-data-for-its-coronavirus-vaccine-candidate-2020-05-18) from its Phase I trial testing a vaccine candidate in people on Monday. Inovio's stock is up 341.2% year-to-date, while the S&P 500 is down 9.5%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 20, 2020 07:31 ET (11:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.